Funding

Vedanta Biosciences

United States · Biotech · Enterprise software

Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection

Visit vedantabio.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Growth$60MAMR Action Fund — Role not disclosedBARDA — Role not disclosedBNP Paribas Asset Management Alts — Role not disclosed

Investors

AMR Action FundGrowthBARDAGrowthBNP Paribas Asset Management AltsGrowth

Coverage

Aug 5, 2026Vedanta Biosciences · Growth

Similar companies

Knowledge WorkTokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.¥4.8B · Series C debt second close
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
Sourcesvedantabio.com ↗